What is the recommended treatment approach for a patient coinfected with Hepatitis B (HBV) and Hepatitis C (HCV)?

Treatment of HBV-HCV Coinfection

Treat HCV with standard direct-acting antiviral (DAA) regimens as you would for HCV monoinfection, while simultaneously providing HBV nucleos(t)ide analogue therapy if the patient is HBsAg-positive. 1

Pre-Treatment Testing Requirements

Before initiating any HCV treatment, mandatory testing includes:

• HBsAg (hepatitis B surface antigen) 1, 2, 3
• Anti-HBc antibodies (hepatitis B core antibody) 1, 2, 3
• Anti-HBs antibodies 1
• HBV DNA level to assess replicative status 1
• HCV RNA to confirm active HCV infection 1
• HIV status if unknown 1
• Hepatitis D virus screening should be performed 1

Treatment Algorithm

Step 1: Treat HCV First (When HCV RNA is Detectable)

Use the same DAA regimens and treatment duration as for HCV monoinfection - there are no modifications needed for coinfection status. 1 Select your DAA regimen based on:

• HCV genotype 4
• Presence or absence of cirrhosis 1
• Prior treatment history 1

Common regimens include glecaprevir/pibrentasvir, sofosbuvir/velpatasvir, or ledipasvir/sofosbuvir for 8-12 weeks depending on these factors. 1, 4

Step 2: Determine Need for Concurrent HBV Treatment

If HBsAg-positive: Start HBV nucleos(t)ide analogue therapy immediately when initiating HCV DAAs. 1 This is non-negotiable prophylaxis against HBV reactivation.

Preferred HBV agents:

• Entecavir 1, 5
• Tenofovir disoproxil fumarate (TDF) 1, 5
• Tenofovir alafenamide (TAF) 1, 5

Critical caveat: If using ledipasvir/sofosbuvir with tenofovir DF, monitor renal function closely due to increased nephrotoxicity risk. 1

If HBsAg-negative but anti-HBc-positive: Do not routinely start HBV prophylaxis, but monitor closely (see monitoring section below). 1 The reactivation risk is very low (0-0.1%) but not zero. 1

Step 3: Duration of HBV Treatment

Continue HBV nucleos(t)ide analogue therapy at minimum until 12 weeks post-HCV treatment completion. 1 After this point:

• If the patient meets standard HBV treatment criteria (elevated HBV DNA, significant fibrosis, or cirrhosis), continue HBV therapy according to standard HBV guidelines 1
• If HBV treatment is stopped after week 12 post-HCV therapy, monitor monthly for reactivation 1
• For patients with cirrhosis or history of HCC, strongly consider continuing HBV therapy indefinitely to prevent liver failure from reactivation 1

Monitoring Protocol

During HCV Treatment (Monthly):

• ALT levels 1
• HBV DNA (especially in HBsAg-positive patients) 1
• HCV RNA at weeks 2,4, end of treatment 4

After HCV Treatment Completion:

For HBsAg-positive patients:

• Monthly monitoring of ALT and HBV DNA for at least 12 weeks 1
• If HBV therapy is discontinued, continue monthly monitoring indefinitely 1

For HBsAg-negative, anti-HBc-positive patients:

• Monthly ALT monitoring 1
• Test HBsAg and HBV DNA if ALT rises or fails to normalize 1

Understanding HBV Reactivation Risk

HBV reactivation occurs in approximately 14% of coinfected patients during or after HCV DAA therapy. 1 In a Taiwanese study of 111 patients treated with sofosbuvir/ledipasvir:

• 100% achieved HCV cure (SVR) 1
• Two-thirds experienced HBV DNA increases (mostly asymptomatic) 1
• 12.2% developed active hepatitis with ALT elevation 1
• Only 2 patients required HBV treatment initiation 1

Critical warning from FDA: HBV reactivation during HCV DAA therapy has resulted in fulminant hepatitis, hepatic failure, and death in patients not receiving HBV prophylaxis. 2, 3

Common Pitfalls to Avoid

Pitfall #1: Failing to test for HBsAg before starting HCV DAAs - this is a boxed warning from the FDA and can result in fatal HBV reactivation. 2, 3

Pitfall #2: Stopping HBV monitoring too early after HCV treatment - reactivation can occur months after HCV clearance, so continue monitoring for at least 12 weeks post-treatment. 1

Pitfall #3: Not starting HBV prophylaxis in HBsAg-positive patients - even if HBV DNA is undetectable, these patients require nucleos(t)ide analogue coverage. 1

Pitfall #4: Using suboptimal HBV agents - avoid lamivudine or adefovir due to resistance concerns; use entecavir, TDF, or TAF. 1, 5

Pitfall #5: Assuming HBsAg-negative patients are safe - while reactivation risk is low (0-0.1%), it still occurs, so monthly ALT monitoring is mandatory. 1

Special Populations

Decompensated cirrhosis (Child-Pugh B or C):

• Treat HCV with sofosbuvir/velpatasvir ± ribavirin depending on renal function 1
• Continue HBV nucleos(t)ide analogues indefinitely 1, 5

Liver transplant recipients:

• Use ledipasvir/sofosbuvir or sofosbuvir/velpatasvir + ribavirin for 12 weeks 1
• Maintain HBV prophylaxis throughout 1

HBV/HCV/HIV triple infection:

• Follow same HCV and HBV treatment principles 1
• Check for drug-drug interactions between DAAs, nucleos(t)ide analogues, and antiretrovirals 1
• Tenofovir-based regimens are preferred as they treat both HBV and HIV 1